research use only
Cat.No.S5979
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HCV Protease |
|---|---|
| Other HIV Inhibitors | Ebselen ABX464 WAY-383487 Oxindole Zingibroside R1 Swertia Bimaculata Extract CQ31 Fostemsavir Tris |
| Molecular Weight | 235.24 | Formula | C10H13N5O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 4097-22-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | ddA, ddAdo | Smiles | NC1=C2N=C[N](C3CCC(CO)O3)C2=NC=N1 | ||
|
In vitro |
DMSO
: 47 mg/mL
(199.79 mM)
Water : 47 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
HIV
HBV
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06405386 | Not yet recruiting | Diabetes type1|Diabetes Mellitus Type 1|Diabetes Autoimmune|Diabetes Mellitus|Distress Emotional |
University of North Carolina Chapel Hill|American Diabetes Association |
May 2024 | Not Applicable |
| NCT06405373 | Not yet recruiting | Diabetes type1|Diabetes Mellitus Type 1|Diabetes Autoimmune|Diabetes Mellitus|Distress Emotional |
University of North Carolina Chapel Hill|American Diabetes Association |
May 2024 | Not Applicable |
| NCT05815342 | Completed | Type2 Diabetes |
Insulet Corporation|Jaeb Center for Health Research |
April 11 2023 | Not Applicable |
| NCT05523362 | Completed | Type 2 Diabetes |
Ian J. Neeland MD|DexCom Inc.|University Hospitals Cleveland Medical Center |
January 15 2022 | Not Applicable |
| NCT04821336 | Completed | Thyroid Cancer |
Institut Claudius Regaud|Cancer Research Center of Toulouse |
April 15 2021 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.